Our transcriptomic characterization supports the new, 2022 adaptation of WHO nomenclature of lymphoid tumors regarding these classes where MYC/BCL6 rearrangements are not further considered as a hit-classifier and the other two types are now defined as IRF4-R LBCL and HGBL-11q, respectively (Table 1). This evidence concerns the gene IRF4 and lymphoid neoplasm.